902 related articles for article (PubMed ID: 25723109)
21. Identification of
Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
Song Z; Yu X; Zhang Y
Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
[TBL] [Abstract][Full Text] [Related]
23. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.
Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
[TBL] [Abstract][Full Text] [Related]
24. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
Qiu X; Montgomery E; Sun B
Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
[TBL] [Abstract][Full Text] [Related]
26. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
[TBL] [Abstract][Full Text] [Related]
27. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.
Yoon HJ; Sohn I; Cho JH; Lee HY; Kim JH; Choi YL; Kim H; Lee G; Lee KS; Kim J
Medicine (Baltimore); 2015 Oct; 94(41):e1753. PubMed ID: 26469915
[TBL] [Abstract][Full Text] [Related]
28. Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack USP6, ROS1 and ETV6 gene rearrangements.
Jebastin JAS; Smith SC; Perry KD; Gupta NS; Alanee S; Carskadon S; Chitale DA; Palanisamy N; Williamson SR
Histopathology; 2018 Aug; 73(2):321-326. PubMed ID: 29617048
[TBL] [Abstract][Full Text] [Related]
29. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
[TBL] [Abstract][Full Text] [Related]
30. Uterine inflammatory myofibroblastic tumors in pregnant women with and without involvement of the placenta: a study of 6 cases with identification of a novel TIMP3-RET fusion.
Cheek EH; Fadra N; Jackson RA; Davila JI; Sukov WR; Uckerman MT; Clayton A; Keeney GL; Halling KC; Torres-Mora J; Schoolmeester JK
Hum Pathol; 2020 Mar; 97():29-39. PubMed ID: 31917155
[TBL] [Abstract][Full Text] [Related]
31. Assessment of ALK Fusions in Uncommon Inflammatory Myofibroblastic Tumors With ALK IHC Positivity but FISH-Equivocal Findings by Targeted RNA Sequencing.
Yao Q; Bai Q; Zhang X; Ji G; Chang H; Cai X; Yu L; Wang J; Zhu X; Zhou X
Arch Pathol Lab Med; 2022 Oct; 146(10):1234-1242. PubMed ID: 35041745
[TBL] [Abstract][Full Text] [Related]
32. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review.
Zhang L; Luan L; Shen L; Xue R; Huang J; Su J; Huang Y; Xu Y; Wang X; Shao Y; Ji Y; Xu C; Hou Y
Virchows Arch; 2023 Mar; 482(3):567-580. PubMed ID: 36624188
[TBL] [Abstract][Full Text] [Related]
33. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer.
Rogers TM; Arnau GM; Ryland GL; Huang S; Lira ME; Emmanuel Y; Perez OD; Irwin D; Fellowes AP; Wong SQ; Fox SB
Sci Rep; 2017 Feb; 7():42259. PubMed ID: 28181564
[TBL] [Abstract][Full Text] [Related]
34. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
[TBL] [Abstract][Full Text] [Related]
35. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
Cools J; Wlodarska I; Somers R; Mentens N; Pedeutour F; Maes B; De Wolf-Peeters C; Pauwels P; Hagemeijer A; Marynen P
Genes Chromosomes Cancer; 2002 Aug; 34(4):354-62. PubMed ID: 12112524
[TBL] [Abstract][Full Text] [Related]
37. A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review.
Liu X; Duan Y; Wang G; Zhu P
Diagn Pathol; 2023 Sep; 18(1):105. PubMed ID: 37735390
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
[TBL] [Abstract][Full Text] [Related]
39. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
Zhang S; Yan B; Zheng J; Zhao J; Zhou J
Oncotarget; 2016 Sep; 7(39):63758-63766. PubMed ID: 27563816
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.
Kerr DA; Thompson LDR; Tafe LJ; Jo VY; Neyaz A; Divakar P; Paydarfar JA; Pastel DA; Shirai K; John I; Seethala RR; Salgado CM; Deshpande V; Bridge JA; Kashofer K; Brčić I; Linos K
Am J Surg Pathol; 2021 Dec; 45(12):1707-1719. PubMed ID: 34001695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
